134
Effective from the early stages of the disease, well tolerated and capable of protecting against cognitive decline. For years, scientific research has been studying to identify therapies that can guarantee patients with multiple sclerosis these objectives and now new data arriving from the European Congress of the European Academy of Neurology (EAN), recently held in Vienna, reveal that for these patients, over 100 thousand in Italy, there is a therapy that manages to achieve these goals.